Is AIM ImmunoTech Stock a Good Investment?
AIM ImmunoTech Investment Advice | AIM |
- Examine AIM ImmunoTech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AIM ImmunoTech's leadership team and their track record. Good management can help AIM ImmunoTech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact AIM ImmunoTech's business and its evolving consumer preferences.
- Compare AIM ImmunoTech's performance and market position to its competitors. Analyze how AIM ImmunoTech is positioned in terms of product offerings, innovation, and market share.
- Check if AIM ImmunoTech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AIM ImmunoTech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AIM ImmunoTech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AIM ImmunoTech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine AIM ImmunoTech Stock
Researching AIM ImmunoTech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company shares are held by company insiders. The company recorded a loss per share of 24.0. AIM ImmunoTech last dividend was issued on the 11th of June 2019. The entity had 1:100 split on the 12th of June 2025.
To determine if AIM ImmunoTech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AIM ImmunoTech's research are outlined below:
| AIM ImmunoTech is way too risky over 90 days horizon | |
| AIM ImmunoTech appears to be risky and price may revert if volatility continues | |
| AIM ImmunoTech has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 113 K. | |
| AIM ImmunoTech has about 27.05 M in cash with (14.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: AIM Sports Group Names Chris Hoppe Executive Vice President |
AIM ImmunoTech Quarterly Long Term Debt |
|
AIM ImmunoTech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AIM ImmunoTech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AIM ImmunoTech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact AIM ImmunoTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises AIM ImmunoTech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-13 | 2022-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-11-15 | 2021-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-05-17 | 2021-03-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2020-08-14 | 2020-06-30 | -0.1 | -0.11 | -0.01 | 10 | ||
2021-03-31 | 2020-12-31 | -0.07 | -0.09 | -0.02 | 28 | ||
2023-05-15 | 2023-03-31 | -0.11 | -0.08 | 0.03 | 27 | ||
2023-03-16 | 2022-12-31 | -0.12 | -0.09 | 0.03 | 25 | ||
2022-08-15 | 2022-06-30 | -0.07 | -0.1 | -0.03 | 42 |
AIM ImmunoTech's market capitalization trends
The company currently falls under 'Nano-Cap' category with a total capitalization of 7.07 M.Market Cap |
|
AIM ImmunoTech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.88) | (2.74) | |
| Return On Capital Employed | 21.33 | 22.40 | |
| Return On Assets | (2.01) | (1.91) | |
| Return On Equity | 13.10 | 13.76 |
Determining AIM ImmunoTech's profitability involves analyzing its financial statements and using various financial metrics to determine if AIM ImmunoTech is a good buy. For example, gross profit margin measures AIM ImmunoTech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AIM ImmunoTech's profitability and make more informed investment decisions.
Evaluate AIM ImmunoTech's management efficiency
AIM ImmunoTech has Return on Asset of (0.9837) % which means that on every $100 spent on assets, it lost $0.9837. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (31.3891) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Return On Capital Employed is very stable compared to the past year. As of the 19th of July 2025, Return On Equity is likely to grow to 13.76, though Return On Tangible Assets are likely to grow to (2.74). At this time, AIM ImmunoTech's Non Current Assets Total are very stable compared to the past year. As of the 19th of July 2025, Non Currrent Assets Other is likely to grow to about 1.2 M, while Other Current Assets are likely to drop about 189.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.02) | (0.02) | |
| Tangible Book Value Per Share | (0.07) | (0.07) | |
| Enterprise Value Over EBITDA | (0.75) | (0.79) | |
| Price Book Value Ratio | (8.39) | (7.97) | |
| Enterprise Value Multiple | (0.75) | (0.79) | |
| Price Fair Value | (8.39) | (7.97) | |
| Enterprise Value | 12.3 M | 18.7 M |
The operational strategies employed by AIM ImmunoTech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.322 |
Basic technical analysis of AIM Stock
As of the 19th of July, AIM ImmunoTech shows the Mean Deviation of 7.28, risk adjusted performance of 0.1728, and Semi Deviation of 5.4. AIM ImmunoTech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm AIM ImmunoTech information ratio, as well as the relationship between the value at risk and expected short fall to decide if AIM ImmunoTech is priced adequately, providing market reflects its regular price of 8.65 per share. Given that AIM ImmunoTech has jensen alpha of 2.41, we suggest you to validate AIM ImmunoTech's prevailing market performance to make sure the company can sustain itself in the future.AIM ImmunoTech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AIM ImmunoTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on AIM ImmunoTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AIM ImmunoTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AIM ImmunoTech's Outstanding Corporate Bonds
AIM ImmunoTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AIM ImmunoTech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AIM bonds can be classified according to their maturity, which is the date when AIM ImmunoTech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACACN 36 15 MAR 27 Corp BondUS009090AA91 | View | |
| ACACN 525 01 APR 29 Corp BondUS00909DAA19 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| ACACN 33 15 JAN 30 Corp BondUS00908PAA57 | View |
Understand AIM ImmunoTech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AIM ImmunoTech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1728 | |||
| Market Risk Adjusted Performance | (1.19) | |||
| Mean Deviation | 7.28 | |||
| Semi Deviation | 5.4 | |||
| Downside Deviation | 6.87 | |||
| Coefficient Of Variation | 571.21 | |||
| Standard Deviation | 12.49 | |||
| Variance | 156.06 | |||
| Information Ratio | 0.1638 | |||
| Jensen Alpha | 2.41 | |||
| Total Risk Alpha | 0.4277 | |||
| Sortino Ratio | 0.298 | |||
| Treynor Ratio | (1.20) | |||
| Maximum Drawdown | 91.33 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 17.86 | |||
| Downside Variance | 47.16 | |||
| Semi Variance | 29.17 | |||
| Expected Short fall | (9.55) | |||
| Skewness | 3.17 | |||
| Kurtosis | 15.11 |
| Risk Adjusted Performance | 0.1728 | |||
| Market Risk Adjusted Performance | (1.19) | |||
| Mean Deviation | 7.28 | |||
| Semi Deviation | 5.4 | |||
| Downside Deviation | 6.87 | |||
| Coefficient Of Variation | 571.21 | |||
| Standard Deviation | 12.49 | |||
| Variance | 156.06 | |||
| Information Ratio | 0.1638 | |||
| Jensen Alpha | 2.41 | |||
| Total Risk Alpha | 0.4277 | |||
| Sortino Ratio | 0.298 | |||
| Treynor Ratio | (1.20) | |||
| Maximum Drawdown | 91.33 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 17.86 | |||
| Downside Variance | 47.16 | |||
| Semi Variance | 29.17 | |||
| Expected Short fall | (9.55) | |||
| Skewness | 3.17 | |||
| Kurtosis | 15.11 |
Consider AIM ImmunoTech's intraday indicators
AIM ImmunoTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AIM ImmunoTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AIM ImmunoTech Corporate Filings
| 15th of July 2025 Other Reports | ViewVerify | |
| 27th of June 2025 Other Reports | ViewVerify | |
8K | 20th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
AIM Stock media impact
There is far too much social signal, news, headlines, and media speculation about AIM ImmunoTech that are available to investors today. This information is accessible both publicly - through AIM ImmunoTech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of AIM-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of AIM ImmunoTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AIM ImmunoTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AIM ImmunoTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AIM ImmunoTech alpha.
AIM ImmunoTech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards AIM ImmunoTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
AIM ImmunoTech Corporate Management
| Wayne Springate | Senior Vice President - Operations | Profile | |
| III Esq | Exec COO | Profile | |
| Ann Coverly | Director Coordinator | Profile | |
| MBA IV | Chief Officer | Profile | |
| Stewart Appelrouth | Director | Profile |
Already Invested in AIM ImmunoTech?
The danger of trading AIM ImmunoTech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AIM ImmunoTech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AIM ImmunoTech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AIM ImmunoTech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (24.00) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between AIM ImmunoTech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.